journal
MENU ▼
Read by QxMD icon Read
search

Lancet Diabetes & Endocrinology

journal
https://www.readbyqxmd.com/read/29329975/risk-of-suicide-and-non-fatal-self-harm-after-bariatric-surgery-results-from-two-matched-cohort-studies
#1
Martin Neovius, Gustaf Bruze, Peter Jacobson, Kajsa Sjöholm, Kari Johansson, Fredrik Granath, Johan Sundström, Ingmar Näslund, Claude Marcus, Johan Ottosson, Markku Peltonen, Lena M S Carlsson
BACKGROUND: Bariatric surgery reduces mortality, but might have adverse effects on mental health. We assessed the risk of suicide and self-harm after bariatric surgery compared with non-surgical obesity treatment. METHODS: Suicide and non-fatal self-harm events retrieved from nationwide Swedish registers were examined in two cohorts. The non-randomised, prospective Swedish Obese Subjects (SOS) study compared bariatric surgery (n=2010; 1369 vertical-banded gastroplasty, 376 gastric banding, and 265 gastric bypass) with usual care (n=2037; recruitment 1987-2001)...
January 9, 2018: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29329974/bariatric-surgery-many-benefits-but-emerging-risks
#2
Matthew J Spittal, Gema Frühbeck
No abstract text is available yet for this article.
January 9, 2018: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29275069/treatment-strategies-for-neuroischaemic-diabetic-foot-ulcers
#3
Fran Game
No abstract text is available yet for this article.
December 20, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29275068/sucrose-octasulfate-dressing-versus-control-dressing-in-patients-with-neuroischaemic-diabetic-foot-ulcers-explorer-an-international-multicentre-double-blind-randomised-controlled-trial
#4
Michael Edmonds, José Luis Lázaro-Martínez, Jesus Manuel Alfayate-García, Jacques Martini, Jean-Michel Petit, Gerry Rayman, Ralf Lobmann, Luigi Uccioli, Anne Sauvadet, Serge Bohbot, Jean-Charles Kerihuel, Alberto Piaggesi
BACKGROUND: Diabetic foot ulcers are serious and challenging wounds associated with high risk of infection and lower-limb amputation. Ulcers are deemed neuroischaemic if peripheral neuropathy and peripheral artery disease are both present. No satisfactory treatment for neuroischaemic ulcers currently exists, and no evidence supports one particular dressing. We aimed to assess the effect of a sucrose octasulfate dressing versus a control dressing on wound closure in patients with neuroischaemic diabetic foot ulcers...
December 20, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29246752/autoimmune-thyroid-disease-during-pregnancy
#5
REVIEW
Simone De Leo, Elizabeth N Pearce
Understanding of changes in thyroid function and the consequences of thyroid disease during pregnancy has rapidly grown in the past two decades, and revised American Thyroid Association guidelines on this topic were published in 2017. This Review explores the association between thyroid autoimmunity and complications during and after pregnancy. Thyroid autoimmunity refers to the presence of antibodies to thyroperoxidase or thyroglobulin, or thyroid-stimulating hormone receptor antibodies (TRAbs), or a combination of these, and is present in up to 18% of pregnant women...
December 12, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29229498/effect-of-once-daily-modified-release-hydrocortisone-versus-standard-glucocorticoid-therapy-on-metabolism-and-innate-immunity-in-patients-with-adrenal-insufficiency-dream-a-single-blind-randomised-controlled-trial
#6
Andrea M Isidori, Mary Anna Venneri, Chiara Graziadio, Chiara Simeoli, Daniela Fiore, Valeria Hasenmajer, Emilia Sbardella, Daniele Gianfrilli, Carlotta Pozza, Patrizio Pasqualetti, Stefania Morrone, Angela Santoni, Fabio Naro, Annamaria Colao, Rosario Pivonello, Andrea Lenzi
BACKGROUND: Conventional treatment of patients with adrenal insufficiency involves administration of glucocorticoids multiple times a day and has been associated with weight gain and metabolic impairment. The optimal glucocorticoid replacement therapy for these patients is highly debated because of the scarcity of evidence from randomised trials. We aimed to establish whether the timing and pharmacokinetics of glucocorticoid replacement therapy affect the metabolism and immune system of patients with adrenal insufficiency...
December 8, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29229497/advanced-neuroendocrine-tumours-of-the-small-intestine-and-pancreas-clinical-developments-controversies-and-future-strategies
#7
REVIEW
Christoph J Auernhammer, Christine Spitzweg, Martin K Angele, Stefan Boeck, Ashley Grossman, Svenja Nölting, Harun Ilhan, Thomas Knösel, Julia Mayerle, Martin Reincke, Peter Bartenstein
In this Review, we discuss clinical developments and controversies in the treatment of neuroendocrine tumours (NETs) that are relevant for clinicians and clinical researchers. We describe advances in genetics, blood-based biomarkers, functional imaging, and systemic therapy of advanced NETs and discuss results of recent phase 3 studies, systemic treatment of advanced disease with peptide receptor radionuclide therapy, biotherapy, chemotherapy, and molecularly targeted therapy, and the potential role of immunotherapy in the treatment of NETs...
December 8, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29229496/turning-back-the-clock-on-adrenal-insufficiency
#8
Gudmundur Johannsson
No abstract text is available yet for this article.
December 8, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29221659/cardiovascular-outcomes-with-glucagon-like-peptide-1-receptor-agonists-in-patients-with-type-2-diabetes-a-meta-analysis
#9
M Angelyn Bethel, Rishi A Patel, Peter Merrill, Yuliya Lokhnygina, John B Buse, Robert J Mentz, Neha J Pagidipati, Juliana C Chan, Stephanie M Gustavson, Nayyar Iqbal, Aldo P Maggioni, Peter Öhman, Neil R Poulter, Ambady Ramachandran, Bernard Zinman, Adrian F Hernandez, Rury R Holman
BACKGROUND: Glucagon-like peptide-1 (GLP-1) receptor agonists are effective glucose-lowering drugs. Findings from cardiovascular outcome trials showed cardiovascular safety of GLP-1 receptor agonists, but results for cardiovascular efficacy were varied. We aimed to examine overall cardiovascular efficacy for lixisenatide, liraglutide, semaglutide, and extended-release exenatide. METHODS: In this systematic review and meta-analysis, we analysed data from eligible trials that assessed the safety and efficacy of GLP-1 receptor agonists compared with placebo in adult patients (aged 18 years or older) with type 2 diabetes and had a primary outcome including, but not limited to, cardiovascular mortality, non-fatal myocardial infarction, and non-fatal stroke...
December 5, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29221658/glp-1-receptor-agonists-differentiation-within-the-class
#10
Simeon I Taylor
No abstract text is available yet for this article.
December 5, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29199116/repaglinide-versus-insulin-for-newly-diagnosed-diabetes-in-patients-with-cystic-fibrosis-a-multicentre-open-label-randomised-trial
#11
Manfred Ballmann, Dominique Hubert, Baroukh M Assael, Doris Staab, Alexandra Hebestreit, Lutz Naehrlich, Tanja Nickolay, Nicole Prinz, Reinhard W Holl
BACKGROUND: As survival among patients with cystic fibrosis has improved in recent decades, complications have become increasingly relevant. The most frequent complication is cystic-fibrosis-related diabetes. The recommended treatment is injected insulin, but some patients are treated with oral antidiabetic drugs to ease the treatment burden. We assessed the efficacy and safety of oral antidiabetic drugs. METHODS: We did a multicentre, open-label, comparative, randomised trial in 49 centres in Austria, France, Germany, and Italy...
November 30, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29199115/frequency-and-phenotype-of-type-1-diabetes-in-the-first-six-decades-of-life-a-cross-sectional-genetically-stratified-survival-analysis-from-uk-biobank
#12
Nicholas J Thomas, Samuel E Jones, Michael N Weedon, Beverley M Shields, Richard A Oram, Andrew T Hattersley
BACKGROUND: Type 1 diabetes is typically considered a disease of children and young adults. Genetic susceptibility to young-onset type 1 diabetes is well defined and does not predispose to type 2 diabetes. It is not known how frequently genetic susceptibility to type 1 diabetes leads to a diagnosis of diabetes after age 30 years. We aimed to investigate the frequency and phenotype of type 1 diabetes resulting from high genetic susceptibility in the first six decades of life. METHODS: In this cross-sectional analysis, we used a type 1 diabetes genetic risk score based on 29 common variants to identify individuals of white European descent in UK Biobank in the half of the population with high or low genetic susceptibility to type 1 diabetes...
November 30, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29199114/cystic-fibrosis-related-diabetes-time-for-oral-drugs
#13
Antoinette Moran
No abstract text is available yet for this article.
November 30, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29199113/genetics-and-biobanks-converge-to-resolve-a-vexing-knowledge-gap-in-diabetes
#14
Jose C Florez
No abstract text is available yet for this article.
November 30, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29195905/diabetes-and-adiposity-a-heavy-load-for-cancer
#15
Yikyung Park, Graham A Colditz
No abstract text is available yet for this article.
November 28, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29195904/worldwide-burden-of-cancer-attributable-to-diabetes-and-high-body-mass-index-a-comparative-risk-assessment
#16
Jonathan Pearson-Stuttard, Bin Zhou, Vasilis Kontis, James Bentham, Marc J Gunter, Majid Ezzati
BACKGROUND: Diabetes and high body-mass index (BMI) are associated with increased risk of several cancers, and are increasing in prevalence in most countries. We estimated the cancer incidence attributable to diabetes and high BMI as individual risk factors and in combination, by country and sex. METHODS: We estimated population attributable fractions for 12 cancers by age and sex for 175 countries in 2012. We defined high BMI as a BMI greater than or equal to 25 kg/m2...
November 28, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29146206/using-big-data-for-non-communicable-disease-surveillance
#17
Ran D Balicer, Miguel Luengo-Oroz, Chandra Cohen-Stavi, Enrique Loyola, Frederiek Mantingh, Liudmyla Romanoff, Gauden Galea
No abstract text is available yet for this article.
November 13, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29129576/cardiometabolic-outcomes-and-mortality-in-medically-treated-primary-aldosteronism-a-retrospective-cohort-study
#18
Gregory L Hundemer, Gary C Curhan, Nicholas Yozamp, Molin Wang, Anand Vaidya
BACKGROUND: Mineralocorticoid receptor (MR) antagonists are the recommended medical therapy for primary aldosteronism. Whether this recommendation effectively reduces cardiometabolic risk is not well understood. We aimed to investigate the risk of incident cardiovascular events in patients with primary aldosteronism treated with MR antagonists compared with patients with essential hypertension. METHODS: We did a cohort study using patients from a research registry from Brigham and Women's Hospital, Massachusetts General Hospital, and their affiliated partner hospitals...
November 9, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29129575/cardiovascular-events-and-target-organ-damage-in-primary-aldosteronism-compared-with-essential-hypertension-a-systematic-review-and-meta-analysis
#19
Silvia Monticone, Fabrizio D'Ascenzo, Claudio Moretti, Tracy Ann Williams, Franco Veglio, Fiorenzo Gaita, Paolo Mulatero
BACKGROUND: There is conflicting evidence, relying on heterogeneous studies, as to whether aldosterone excess is responsible for an increased risk of cardiovascular and cerebrovascular complications in patients with primary aldosteronism. We aimed to assess the association between primary aldosteronism and adverse cardiac and cerebrovascular events, target organ damage, diabetes, and metabolic syndrome, compared with the association of essential hypertension and these cardiovascular and end organ events, by integrating results of previous studies...
November 9, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29129574/primary-aldosteronism-and-cardiovascular-risk-before-and-after-treatment
#20
John W Funder
No abstract text is available yet for this article.
November 9, 2017: Lancet Diabetes & Endocrinology
journal
journal
47944
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"